2018
Genomics of Peritoneal Malignancies
Karunasena E, Sham J, McMahon KW, Ahuja N. Genomics of Peritoneal Malignancies. Surgical Oncology Clinics Of North America 2018, 27: 463-475. PMID: 29935683, DOI: 10.1016/j.soc.2018.02.004.Peer-Reviewed Original ResearchConceptsPeritoneal malignancyPeritoneal metastasisSimilar genetic mutationsEpithelial-mesenchymal transitionBiologic therapySurgical resectionMetastatic lesionsPredictive markerPrimary tumorIntraabdominal organsAggressive cancerMultiple cancersMetastasisMalignancyGenetic mutationsCancerOrgansResectionChemotherapyPeritoneumTherapyLesionsTumorsAbdomenAdjunctExtraskeletal versus Skeletal Ewing Sarcoma in the adult population: Controversies in care
Lynch AD, Gani F, Meyer CF, Morris CD, Ahuja N, Johnston FM. Extraskeletal versus Skeletal Ewing Sarcoma in the adult population: Controversies in care. Surgical Oncology 2018, 27: 373-379. PMID: 30217290, DOI: 10.1016/j.suronc.2018.05.016.Peer-Reviewed Original ResearchConceptsExtraskeletal Ewing's sarcomaCharlson-Deyo scoreOverall survivalTriple therapyCombination therapyLocal therapyEwing's sarcomaProportional hazards regression analysisHazards regression analysisSkeletal Ewing sarcomaEwing's sarcoma patientsAdult patientsIndependent predictorsEE patientsSarcoma patientsRisk factorsTreatment characteristicsSmall tumorsOutcome differencesPatientsTherapyAdult populationLack of consensusChemotherapyRegression analysis
2017
Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells
Sharma A, Vatapalli R, Abdelfatah E, McMahon K, Kerner Z, Guzzetta A, Singh J, Zahnow C, Baylin S, Yerram S, Hu Y, Azad N, Ahuja N. Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells. PLOS ONE 2017, 12: e0176139. PMID: 28445481, PMCID: PMC5405959, DOI: 10.1371/journal.pone.0176139.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsATP-Binding Cassette TransportersAzacitidineCaco-2 CellsCamptothecinCell AdhesionCell Line, TumorCell ProliferationColorectal NeoplasmsDNA MethylationDNA RepairGene ExpressionGene Expression ProfilingHCT116 CellsHumansIrinotecanLong Interspersed Nucleotide ElementsMiceMice, Inbred NODMice, SCIDConceptsCRC cell linesColorectal cancerMultiple CRC cell linesPhase 1/2 clinical trialCell linesMetastatic colorectal cancerMajority of patientsNOD-SCID miceColorectal cancer cellsSoft agar assayInitial therapyMetastatic settingCytotoxic chemotherapyCRC treatmentClinical efficacyCancer deathTumor regressionClinical trialsDNA demethylating agentVivo xenograftsChemotherapeutic agentsCancer cellsHCT116 cell linesAgar assayChemotherapy
2015
Time to Chemotherapy After Abdominoperineal Resection: Comparison Between Primary Closure and Perineal Flap Reconstruction
Althumairi AA, Canner JK, Ahuja N, Sacks JM, Safar B, Efron JE. Time to Chemotherapy After Abdominoperineal Resection: Comparison Between Primary Closure and Perineal Flap Reconstruction. World Journal Of Surgery 2015, 40: 225-230. PMID: 26336877, DOI: 10.1007/s00268-015-3224-0.Peer-Reviewed Original ResearchConceptsFlap reconstruction groupAdjuvant chemotherapyFlap reconstructionPrimary closureAbdominoperineal resectionWound complicationsRectal adenocarcinomaReconstruction groupWound healingPerineal flap reconstructionPerineal wound complicationsPrimary closure groupPerineal wound closureLength of healingRetrospective reviewClosure groupChemotherapyPatientsPerineal defectsWound closureHealingResectionComplicationsAdenocarcinomaLength of time